{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"ANC \\<0.5 × 109/L, absolute lymphocyte count (ALC) \\<0.1 × 109/L, platelet count \\<20,000/mm3, or bleeding requiring transfusion. The first of 2 consecutive days for which cell counts drop below these cutoff levels was recorded as the date of myeloablation.\n\nSince the two treatments were administered consecutively with 1 day rest, the time to myeloablation and myeloablation rate was measured after both treatments were administered.\n\nComparison of sequence effect was not planned in the study and due to small sample size, it was not performed.","dispersionType":"Standard Deviation","groups":[{"description":"Open-label, randomized, cross-over design study where Propylene Glycol Free Melphalan and Alkeran were assessed in the same multiple myeloma patients","id":"OG000","title":"Open-label, Randomized, Cross-over Study"}],"paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population was defined as all patients who received at least one dose of Melphalan HCl for Injection (Propylene Glycol-Free) or Alkeran for Injection. All efficacy analyses were to be performed on the ITT population.","reportingStatus":"POSTED","timeFrame":"30 days","title":"Determination of Myeloablation Following Melphalan-alkeran Sequence and Alkeran-melphalan Sequence Followed by ASCT","type":"SECONDARY","unitOfMeasure":"days"}